{
  "Cancer Histology Subtype (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1049, 
        1055
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1334, 
        1340
      ]
    }
  ], 
  "Cancer Histology Type (Ov)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1056, 
        1065
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1341, 
        1350
      ]
    }
  ], 
  "Clinical History Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        793, 
        816
      ]
    }
  ], 
  "Comments Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2114, 
        2134
      ]
    }
  ], 
  "Final Diagnosis Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        913, 
        940
      ]
    }
  ], 
  "Laterality (Ov)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        942, 
        946
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2068, 
        2072
      ]
    }
  ], 
  "Macroscopic/Gross Description Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        515, 
        544
      ]
    }
  ], 
  "Microscopic Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1922, 
        1957
      ]
    }
  ], 
  "Nature of Specimen Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1999, 
        2025
      ]
    }
  ], 
  "Neoplasm Behaviour (Ov)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1067, 
        1075
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1351, 
        1358
      ]
    }
  ], 
  "Neoplasm Grade Value (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1132, 
        1133
      ]
    }
  ], 
  "Neoplasm Grade-Score Name (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1114, 
        1124
      ]
    }
  ], 
  "Organ/Body Structure (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        947, 
        953
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2073, 
        2079
      ]
    }
  ], 
  "Relative Distance (Ov)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        992, 
        1019
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2093, 
        2111
      ]
    }
  ], 
  "Supplementary Report Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1392, 
        1424
      ]
    }
  ], 
  "__text": "MSH|^~\\&|PathSys|Associated Pathologists, LLC d/b/a PathGroup^44D1053014^CLIA|eMARCPlus|TN Cancer Registry|20170919125830||ORU^R01^ORU_R01|201709191258300001|P|2.5.1|TN||||||||VOL_V_40_ORU_R01-CCR1^NAACCR_CP\nOBR|1||17-21-008880^PathSys^44D1053014^CLIA|11529-5^SURGICAL PATH REPORT^LN|||20170901000000|||||||20170901000000|&Breast, Stereotactic biopsy|1457524209^^^^^^MD^^CMS^D^^^NPI||||||20170905000000|||F||||||C50.812^Malignant neoplasm of overlapping sites of left female breast^I10|1083715031&&&&&&&&CMS\n\n\n\n\n\n\n\nPath report.gross description\n\nReceived in formalin labeled \", irregular mass with abnormal enhancement left breast middle depth 4.8 cm from nipple\" are 3.0 mL of tan-yellow lobulated pieces of breast tissue. The specimen is entirely submitted in 2 cassettes, each M/1. (AES)\n\n\nPath report.relevant Hx\n\nHistory - Irregular mass, abnormal enhancement left breast, middle depth, 4.8 cm from nipple\n\n\nPath report.final diagnosis\n\nLeft breast, abnormal enhancement at middle depth 4.8 centimeters from nipple: MRI-guided needle biopsy:   Ductal carcinoma, invasive, no special type, with:     Estimated Nottingham grade: 3 (tubule formation 3, nuclear grade 3, mitotic       score 2).     Extent: Involves 3 cores (greatest confluent invasive carcinoma length 5       millimeters).     Lymphovascular invasion: Not seen.   Ductal carcinoma in situ (DCIS): Not seen. See comment.\n\n\nPath report.supplemental reports\n\nHormone Receptor report: NEOPLASTIC CELLS ARE NEGATIVE FOR NUCLEAR ESTROGEN RECEPTOR. NEOPLASTIC CELLS ARE NEGATIVE FOR NUCLEAR PROGESTERONE RECEPTOR. NEOPLASTIC CELLS ARE NEGATIVE FOR HER2 BY IMMUNOHISTOCHEMISTRY (0+). CONFIRMATORY HER2 BY FISH ASSAY IS PENDING AND WILL BE REPORTED SEPARATELY. ## End of auxiliary report ## Fish Report: FISH - NEGATIVE for HER2 oncogene amplification by FISH analysis  NEGATIVE for chromosome 17 polysomy by FISH analysis       ## End of auxiliary report ##\n\n\nPath report.microscopic examination\n\nMicroscopic examination is performed.\n\n\nPath report.site of origin\n\nIrregular mass with abnormal enhancement left breast middle depth 4.8 cm from nipple\n\n\nPath report.comments\n\nComments - Assessment of hormone receptor and HER2 status is pending and will be reported separately. The report was phoned to the Breast Imaging Center, 09/05/2017. FISH Comments - The HER2 FISH assay (Abbott Molecular/Vysis, Inc.) did not reveal amplification of the HER2 oncogene. A ratio of HER-2 gene signals to the centromeric control probe of chromosome 17 (CEP 17) signals was 1.06 and a Her2 copy number of 2.12, (ratio less than 2.0 and Her2 copy number <4), indicating absence of amplification. There was no evidence of polysomy/polyploidy or genetic heterogeneity. Clinical correlation is recommended.    A ratio less than 2.0 and Her2 copy number less than 4 indicates absence of amplification.  A ratio less than 2.0 and Her2 copy number greater or equal to 4 and less than 6 indicates an equivocal value and per ASCO/CAP guidelines, requires reflex to another (IHC for Her2) test.  A ratio greater than or equal to 2.0 or average Her2 copy number greater or equal to 6 indicates gene amplification.    Regions of invasive tumor were defined by a pathologist. The tumor was fixed in formalin (recommended 6-72hrs). Tumor fixed outside the recommended fixation time should be interpreted with caution. Controls were performed and provided the anticipated results. This case has been reviewed by at least 2 observers.\n\n\n"
}